*P<0.05 vs. intact control (Group I) #P<0.05 vs. STZ-diabetes (Group II)

Figure 2: Representative Western blots and densitometric analysis of total glial fibrillary acidic protein (GFAP) in protein fractions obtained from the three brain regions of control and experimental rats (data expressed as arbitrary units, n=7): cerebral cortex (A), hippocampus (B), and cerebellum (C). A significant increase in GFAP from cortex and hippocampus of STZ-diabetic rats (II group) is observed. Note the appearance of low-molecular weight GFAP polypeptides in the same brain regions of STZ-diabetic rats. C60HyFn leads to normalization of astrogliosis marker content in these two brain regions injured in the conditions of experimental hyperglycemia. C60HyFn has appeared to display similar efficacy against reactive gliosis regardless of regime of administration.